Toll-like receptors as therapeutic targets for cancer

Drug Discovery Today

Volumn 19, Issue 4, 2014, Pages 379-382

  Holldack, Johanna ^a  

^a Telormedix   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; IMIDAZOQUINILINE 852A; IMIQUIMOD; RESIQUIMOD; TMX 101; TMX 202; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT;

ADVANCED CANCER; ANUS CANCER; BLADDER CANCER; BLADDER IRRITATION; BLEEDING; BONE MARROW SUPPRESSION; CANCER THERAPY; CARCINOMA IN SITU; CARDIOTOXICITY; DRUG SAFETY; DRUG TARGETING; FEVER; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; MELANOMA; MYCOBACTERIOSIS; NONHUMAN; RECEPTOR UPREGULATION; REVIEW; SKIN CANCER; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; IMMUNOLOGY; NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TOLL-LIKE RECEPTORS;

EID: 84899555500     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.08.020     Document Type: Short Survey

References (28)

1. G.K. Hansson, and K. Edfeldt Toll to be paid at the gateway to the vessel wall Arterioscler. Thromb. Vasc. Biol. 25 2005 1085 1087
2. X. Du et al. Three novel mammalian toll-like receptors: gene structure, expression, and evolution Eur. Cytokine Netw. 11 2000 362 371
3. T.H. Chuang, and R.J. Ulevitch Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9 Eur. Cytokine Netw. 11 2000 372 378
4. K. Tabeta et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection Proc. Natl. Acad. Sci. U.S.A. 101 2004 3516 3521
5. A. Pichlmair, and C. Reis e Sousa Innate recognition of viruses Immunity 27 2007 370 383
6. B. Salaun et al. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 13 2007 4565 4574
7. T. Kawai, and S. Akira Innate immune recognition of viral infection Nat. Immunol. 7 2006 131 137
8. P. Sansonetti The innate signalling of dangers and the dangers of innate signalling Nat. Immunol. 7 2006 1237 1242
9. M.J. Smyth et al. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity Adv. Immunol. 90 2006 1 50
10. M.A. Cheever Twelve immunotherapy drugs that could cure cancers Immunol. Rev. 222 2008 357 368
11. W.B. Coley The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases Clin. Orthop. Relat. Res. 262 1991 3 11
12. B. Wiemann, and C.O. Starnes Coley's toxins, tumor necrosis factor and cancer research: a historical perspective Pharmacol. Ther. 64 1994 529 564
13. D.L. Lamm et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder N. Engl. J. Med. 325 1991 1205 1209
14. K.B. Gorden et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8 J. Immunol. 174 2005 1259 1268
15. K.S. Gorski et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists Int. Immunol. 18 2006 1115 1126
16. P.L. Witt et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients Cancer Res. 53 1993 5176 5180
17. A.Z. Dudek et al. First in human Phase I trial of 852A, a novel systemic Toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer Clin. Cancer Res. 13 2007 7119 7125
18. R. Dummer et al. An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma Clin. Cancer Res. 14 2008 856 864
19. M. Geller et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers Cancer Immunol. Immunother. 59 2010 1877 1884
20. M. Kaspari et al. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma Br. J. Dermatol. 147 2002 757 759
21. D.R. Pachman et al. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia Am. J. Obstet. Gynecol. 206 42 2012 e1 e7
22. C. Iavazzo et al. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia Int. J.Gynaecol. Obstet. 101 2008 3 10
23. M. van Seters et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod N. Engl. J. Med. 358 2008 1465 1473
24. M. Shackleton et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand Cancer Immun. 4 2004 9
25. S. Adams et al. Immunization of malignant melanoma patients with full length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant J. Immunol. 181 2008 776 784
26. A. Smorlesi et al. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma Gene Ther. 12 2005 1324 1332
27. S.J. Dovedi et al. Systemic delivery of a TLR-7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma Blood 121 2013 251 259
28. S. Adams Toll-like receptor agonists in cancer therapy Future Med. 1 2009 949 964